TPST | Tempest Therapeutics, Inc. | [NASD]
Index- P/E- EPS (ttm)-2.67 Insider Own3.23% Shs Outstand13.76M Perf Week-12.74%
Market Cap23.79M Forward P/E- EPS next Y-2.20 Insider Trans0.00% Shs Float10.18M Perf Month7.56%
Income-34.90M PEG- EPS next Q-0.52 Inst Own71.30% Short Float / Ratio0.77% / 0.32 Perf Quarter10.78%
Sales- P/S- EPS this Y58.60% Inst Trans-0.36% Short Interest0.08M Perf Half Y7.56%
Book/sh0.80 P/B2.31 EPS next Y-0.50% ROA-64.00% Target Price19.00 Perf Year-52.69%
Cash/sh1.78 P/C1.04 EPS next 5Y- ROE-153.60% 52W Range1.06 - 4.21 Perf YTD60.87%
Dividend- P/FCF- EPS past 5Y60.50% ROI- 52W High-56.10% Beta0.90
Dividend %- Quick Ratio3.30 Sales past 5Y- Gross Margin- 52W Low74.53% ATR0.26
Employees19 Current Ratio3.30 Sales Q/Q- Oper. Margin- RSI (14)41.30 Volatility10.23% 13.11%
OptionableNo Debt/Eq0.95 EPS Q/Q53.20% Profit Margin- Rel Volume0.57 Prev Close2.05
ShortableYes LT Debt/Eq0.81 EarningsMay 10 AMC Payout- Avg Volume246.86K Price1.85
Recom1.50 SMA20-11.63% SMA50-13.76% SMA200-2.06% Volume141,196 Change-9.76%
May-25-23 05:00PM
May-19-23 04:05PM
May-10-23 04:15PM
Apr-28-23 08:00AM
Apr-27-23 04:58PM
06:41PM Loading…
Apr-26-23 06:41PM
Apr-17-23 09:00AM
Mar-22-23 05:26PM
Mar-15-23 04:05PM
Mar-14-23 04:30PM
Nov-22-22 04:05PM
Nov-10-22 09:00AM
Nov-08-22 08:00AM
Nov-02-22 08:00AM
Oct-06-22 08:00AM
08:00AM Loading…
Sep-07-22 08:00AM
Aug-15-22 08:00AM
Jul-07-22 08:00AM
Jun-09-22 08:00AM
Jun-06-22 04:05PM
May-26-22 04:57PM
May-13-22 08:00AM
Apr-27-22 10:01AM
Apr-08-22 01:00PM
Mar-29-22 04:00PM
Mar-10-22 08:00AM
Mar-08-22 04:30PM
Feb-09-22 08:00AM
Nov-18-21 08:00AM
07:00AM Loading…
Nov-12-21 07:00AM
Nov-10-21 04:05PM
Nov-09-21 08:00AM
Nov-08-21 08:00AM
Oct-01-21 08:00AM
Sep-20-21 08:00AM
Sep-13-21 08:00AM
Sep-09-21 04:01PM
Aug-12-21 04:01PM
Aug-09-21 08:00AM
Jul-09-21 08:00AM
Jul-01-21 04:00PM
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.